Curis (NASDAQ:CRIS) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Curis (NASDAQ:CRIS) from a strong sell rating to a hold rating in a research report report published on Saturday morning.

A number of other equities analysts also recently weighed in on CRIS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Curis in a research note on Monday, August 17th. Finally, Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $43.00.

Curis Trading Down 1.9%

NASDAQ CRIS opened at $1.58 on Friday. The business’s 50-day moving average price is $5.13 and its 200 day moving average price is $11.15. Curis has a twelve month low of $1.50 and a twelve month high of $39.00. The company has a market capitalization of $3.30 million, a PE ratio of -0.11 and a beta of 3.13.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative return on equity of 2,365.94% and a negative net margin of 80.29%. Equities analysts predict that Curis will post -24.23 EPS for the current year.

Institutional Trading of Curis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC raised its holdings in Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 10,586 shares during the period. XTX Topco Ltd purchased a new position in shares of Curis in the 4th quarter valued at $26,000. Focused Wealth Management Inc acquired a new position in shares of Curis during the 2nd quarter valued at $26,000. BlackRock Inc. acquired a new position in shares of Curis during the 2nd quarter valued at $28,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 8,973 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.